Home > Boards > US Listed > Biotechs >

Synaptogenix (SNPX)

SNPX RSS Feed
Add SNPX Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach, Cyosol, Battle Ready
Search This Board: 
Last Post: 5/7/2021 7:20:00 AM - Followers: 92 - Board type: Free - Posts Today: 0


 

Description:
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. For more information, visit: https://www.synaptogen.com/

Market Information (as of February 3, 2021):
Symbol: SNPX
Stock Price: $2.80
Market Cap: $39,291,045
Outstanding Shares: 14,032,516
Warrants, options & preferred stock:

Pre-funded Warrants:
- 333,333 Pre-funded Warrants to purchase 333,333 shares of Common Stock, with an exercise price of $0.01 per share ($3,333)

Investor Warrants (expires February 2022):
- 9,335,533 Series E Warrants to purchase 9,335,533 shares of Common Stock, with an exercise price of $2.1275 per share ($19,861,346)

Spin-off Warrants (expires December 2, 2025):
- 157,792 Series A Warrants to purchase up to 157,792 shares of Common Stock with an exercise price of $49.70 per share ($7,842,262)
- 623,250 Series B Warrants to purchase up to 623,250 shares of Common Stock with an exercise price of $19.88 per share ($12,390,210)
- 908,464 Series C Warrants to purchase up to 908,464 shares of Common Stock with an exercise price of $9.94 per share ($9,030,132)
- 2,221,820 Series D Warrants to purchase up to 2,221,820 shares of Common Stock with an exercise price of $3.98 per share ($8,842,844)

Investor Warrants (expires January 25, 2026):
- 9,335,533 Series F Warrants to purchase up to 9,335,533 shares of Common Stock with an exercise price of $1.725 per share ($16,103,794)
 
Placement Agent Warrants (expires January 29, 2026):
- 933,553 Placement Agent Warrants to purchase up to 933,553 shares of Common Stock with an exercise price of $1.725 per share ($1,610,379)
 
To be raised from exercised warrants: $75,684,300
Fully diluted shares (Outstanding Shares + Warrants): 37,881,794
Fully diluted market cap: $106,069,023

Reports:
Roth report (2018): https://pdfhost.io/v/i@2x9BB+F_37943455120180308NTRPRothInitpdf.pdf
Maxim report (2018): https://pdfhost.io/v/agpp@2Q+o_379427337NTRPinitiationpdf.pdf
Janney report (2019): https://pdfhost.io/v/iQV43NGcT_413879072NTRPInitiation06182019pdf.pdf

Press Releases:
Phase 2a results (2015): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-its-phase-2a-study-of-bryostatin-1-in-alzheimers-disease-300038367.html

Exploratory Phase 2b results (2017): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-phase-2-study-of-bryostatin-1-for-moderate-to-severe-alzheimers-disease-300448563.html
Exploratory Phase 2b analysis (2018): https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html

Confirmatory Phase 2b results (2019): https://www.prnewswire.com/news-releases/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease-300913655.html
Confirmatory Phase 2b analysis (2020): https://www.prnewswire.com/news-releases/neurotrope-provides-corporate-update-after-completing-bryostatin-1-data-analysis-for-advanced-alzheimers-disease-trial-300991105.html

Scientific Articles:
[P2a & CU results] "Bryostatin Effects on Cognitive Function and PKC epsilon in Alzheimer’s Disease Phase IIa and Expanded Access Trials" (2017): https://pdfhost.io/v/XAcILs@Hc_jad2F20172F5822Fjad582jad1701612Fjad58jad170161pdf.pdf
[Exploratory P2b results] "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Ef?cacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease" (2018): https://pdfhost.io/v/GEa58CPiF_farlow2018pdf.pdf
[Memantine results] "Memantine in Moderate-to-Severe Alzheimer's Disease" (2003): https://www.nejm.org/doi/full/10.1056/NEJMoa013128
More scientific articles: https://pdfhost.io/v/.~Rt1cU63_bryo1.pdf

Patents:
Patents by Daniel L. Alkon: https://patents.justia.com/inventor/daniel-l-alkon
Patents by Daniel L. Alkon (grants only): http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L.&d=PTXT
Patents by Daniel L. Alkon (applications only): http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L&d=PG01

Media:
"A new era for treating diseases of the brain" (2008): https://youtu.be/W1pdg1kvQHI
"Rockefeller Institute drug provides hope for Alzheimer’s treatment" (2015): https://www.wvgazettemail.com/news/rockefeller-institute-drug-provides-hope-for-alzheimer-s-treatment/article_bf5bab5f-e40e-5f47-95ca-666f14b795e0.html
"The Scoop: Alzheimer’s Drug Tries to Build Up a Head of Steam" (2018): https://www.genengnews.com/magazine/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/
"Advancements in Alzheimer’s Treatment: Interview with Dr. Daniel Alkon" (2018): https://newyork.legalexaminer.com/health/senior-care/advancements-in-alzheimers-treatment-interview-with-dr-daniel-alkon/
"Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story" (2019): https://soundcloud.com/levine-media-group/company-seeks-to-prove-marine-derived-alzheimers-drug-is-no-fish-story
"Pizza Hut co-founder’s compassionate-care Alzheimer’s trial leads to hope for others" (2019): https://www.kansas.com/news/business/biz-columns-blogs/carrie-rengers/article229253744.html
"After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug" (2019): https://www.npr.org/sections/health-shots/2019/05/03/718754791/after-a-big-failure-scientists-and-patients-hunt-for-a-new-type-of-alzheimers-d
Dr. Alkon at Alzheimer's Solutions Conference (2019): https://www.youtube.com/watch?v=bP5GcAplXls
How an Alzheimer’s ‘cabal’ thwarted progress toward a cure (2019): https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/
Charles Ryan On Treating Alzheimer's Disease (2019): https://tdameritradenetwork.com/video/rB4AoWt8Hk2Ba5865CUHvQ
The Impacts of Alzheimer's Disease are Growing (2019): https://www.youtube.com/watch?v=x4NkJqASGZc
Ellis Martin Report with Neurotrope's Dr Daniel Alkon: Successfully Reversing Alzheimer's Disease? (2019): https://www.youtube.com/watch?v=KwkiUj2uGgA

Links:
Investor relations: https://www.synaptogen.com/ir/
SEC filings:
Neurotrope Inc: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001513856
Synaptogenix Inc: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001571934
Bryostatin vs. Memantine vs. Placebo comparison: https://i.imgur.com/579PX0L.jpg
Test comparison: https://i.imgur.com/s61opUd.jpg
BryoLogyx: https://bryologyx.com/
NeuroDiagnostics: https://www.ndx-discern.com/
Ongoing trial: https://clinicaltrials.gov/ct2/show/NCT04538066

 
SNPX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#16438  Sticky Note This has nothing to do with gene editing. Cyosol 10/23/20 01:55:42 PM
#16239  Sticky Note Neurotrope is a front for old money and XenaLives 08/29/20 06:05:05 AM
#16205  Sticky Note FDA trial results. Includes Statistical plan and trial runncoach 07/08/20 08:25:53 PM
#17143   Alkon said we would get the peer reviewed runncoach 05/07/21 07:20:00 AM
#17142   I can't find anything either. My guess is Cyosol 05/07/21 12:45:33 AM
#17141   I looked yesterday but I think the PR runncoach 05/06/21 04:28:45 PM
#17140   Any word on the Sachs Forum presentation? Battle Ready 05/06/21 01:19:42 PM
#17139   Got it, thanks!! That explains some of Battle Ready 04/30/21 10:10:51 AM
#17138   Probably because the S1 wasn't declared effective until yesterday. Cyosol 04/30/21 09:47:07 AM
#17137   Now $SNPX is a new front for old money. Investor2014 04/29/21 09:20:05 AM
#17136   I'm surprised that we never saw any selling Battle Ready 04/28/21 03:46:28 PM
#17135   Here's the official PR. I didn't know runncoach 04/26/21 03:43:40 PM
#17134   Thanks RC for the heads-up, as always!! Battle Ready 04/26/21 03:39:11 PM
#17133   Looks like we'll be a "spot light" presenter runncoach 04/26/21 08:37:53 AM
#17132   Nope, but sometimes it does. That's one of runncoach 04/25/21 08:43:41 AM
#17131   Posthoc analysis always leads to successful trials!!! Investor2014 04/25/21 08:32:36 AM
#17130   "All trials that NIH support are guaranteed to succeed!!!" runncoach 04/25/21 08:31:05 AM
#17129   All trials that NIH support are guaranteed to succeed!!! Investor2014 04/25/21 07:53:46 AM
#17128   Yes showing bryostatin improves cognition for the third runncoach 04/25/21 07:51:38 AM
#17127   .... Investor2014 04/25/21 07:20:20 AM
#17126   Maybe three times lucky proving in controlled trials Investor2014 04/25/21 05:41:01 AM
#17125   Still holding position here still confident the results Whoopddew 04/24/21 10:34:47 PM
#17124   Depends on how the market perceives it. A Cyosol 04/24/21 07:03:32 PM
#17123   Yes it is. The point was positive trend runncoach 04/24/21 04:13:23 PM
#17122   It’s hard to compare trials that measure results Theburg 04/24/21 04:03:45 PM
#17121   Yeah if we're going to think big then runncoach 04/24/21 11:10:40 AM
#17120   I am allowing myself to think big here. Theburg 04/24/21 08:16:45 AM
#17119   That was mentioned by the CEO.at an investor runncoach 04/24/21 06:50:42 AM
#17118   The company said estimated end of trial is Theburg 04/24/21 04:44:43 AM
#17117   Do we have a list of penny stock runncoach 04/23/21 03:59:16 PM
#17116   SYNTAPTOGENIX THE PENNY STOCK SCAM FORMERLY KNOWN AS rayovacAAA 04/23/21 02:49:03 PM
#17115   Q4 2022 Cyosol 04/13/21 11:19:44 PM
#17114   Are the phase two results this year or CYDYWinning 04/13/21 10:43:41 PM
#17113   Which profits? The warrants that were issued in Cyosol 04/12/21 09:48:20 AM
#17112   I love it when there is no proof runncoach 04/12/21 08:57:58 AM
#17111   I think it's wrong for the same crew XenaLives 04/12/21 08:52:25 AM
#17110   DUH - the guys that owned a bunch XenaLives 04/12/21 08:49:46 AM
#17109   I think that's the point. Dilution will continue Cyosol 04/11/21 10:12:14 PM
#17108   And I'm still asking for links of who runncoach 04/11/21 07:51:00 PM
#17107   I am referring to the Neurotrope crew that XenaLives 04/11/21 06:52:15 PM
#17106   Oh so just an opinion then. Not a runncoach 04/11/21 04:04:47 PM
#17105   The reason the stock is "exempt from registration requirements".... XenaLives 04/11/21 03:56:49 PM
#17104   Page 13 in the peer reviewed article does runncoach 04/11/21 12:59:30 PM
#17103   Thanks Coach, for your response. Just wondering, if Theburg 04/11/21 11:36:52 AM
#17102   Huh? runncoach 04/11/21 11:21:48 AM
#17101   Sounds like the accredited investors the profited from XenaLives 04/11/21 09:58:23 AM
#17100   I believe at one time it was reported runncoach 04/10/21 01:54:09 PM
#17099   In the previous trial, were there a difference Theburg 04/10/21 11:22:17 AM
#17098   All proposals approved: Cyosol 04/08/21 07:20:34 PM
#17097   Nope. Investor2014 04/07/21 03:42:24 PM
#17096   Anyone sign up for the shareholder's webcast tomorrow? runncoach 04/06/21 02:25:34 PM
#17095   Nothing really new but was published today. runncoach 04/05/21 05:09:12 PM
#17094   Did not realize that either. runncoach 04/04/21 09:20:56 PM
PostSubject
Consent Preferences